New hope for moms with hepatitis b: drug may stop baby from getting the virus
NCT ID NCT05853718
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study is testing a drug called TAF (tenofovir alafenamide) in pregnant women with chronic hepatitis B. The goal is to see if taking TAF daily from week 28-32 of pregnancy until delivery can prevent the baby from catching the virus. Researchers will also check how the drug moves through the mother's body and look for any safety issues in both mother and child. About 50 women aged 20-40 with high virus levels are being recruited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tenofovir alafenamide (TAF) tablets
- What this could lead to
- If successful, this could show that TAF is a safe and effective option to prevent passing hepatitis B from mother to baby during childbirth.
- What could go wrong
- This is a small, single-center phase 4 study with only 50 participants, so results may not apply broadly. Risks include unknown effects on the infant and potential side effects from the drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hangzhou First People's Hospital
RECRUITINGHangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a new injection tame chronic hepatitis b?
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Could common hepatitis b drugs damage kidneys? a study digs into the data
- Can fatty liver and hepatitis b together harm kidneys? a study digs into the data